Results 71 to 80 of about 282,710 (262)

Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression

Cell Death and Disease, 2021
Dysregulation of transforming growth factor-beta (TGFβ) signaling has been implicated in liver carcinogenesis with both tumor promoting and inhibiting activities.
Haichuan Wang, Pan Wang, Meng Xu, Xinhua Song, Hong Wu, Matthias Evert, Diego F. Calvisi, Yong Zeng, Xin Chen   +8 more
doaj   +1 more source

Direct Activation of HSP90A Transcription by c-Myc Contributes to c-Myc-induced Transformation [PDF]

Journal of Biological Chemistry, 2004
The c-myc proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and differentiation and implicated in inducing tumorigenesis. Understanding the function of c-Myc and its role in cancer depends upon the identification of c-Myc target genes.
Teng, Shu-Chun, Chen, Yung-Yi, Su, Yi-Ning, Chou, Po-Chien, Chiang, Yu-Chi, Tseng, Shun-Fu, Wu, Kou-Juey   +6 more
openaire   +2 more sources

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

A novel mechanism by which c-MYC is aberrantly activated by epigenetic silencing of its antisense lncRNA in colon cancer

Frontiers in Genetics
BackgroundProto-oncogenes are abnormally activated in nearly all types of tumors. However, the epigenetic mechanism of proto-oncogene activation has not yet been well elucidated.MethodsThe present study involved the construction of a double-stranded cDNA
Xuming Hu, Xuming Hu, Xuming Hu, Ye Wei, Meiying Zhang, Chunfeng Dou, Liping Wang, Gul Zaib, Huixian Wu, Wang Guo, Xiaoyuan Wang, Shihao Chen, Qi Xu, Qi Xu, Qi Xu, Mingzhou Guo, Hengmi Cui, Hengmi Cui, Hengmi Cui, Hengmi Cui   +19 more
doaj   +1 more source

C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.

PLoS ONE, 2014
ObjectivesVarious studies have investigated the prognostic value of C-MYC aberrations in diffuse large B-cell lymphoma (DLBCL). However, the role of C-MYC as an independent prognostic factor in clinical practice remains controversial. A systematic review
Kuangguo Zhou, Danmei Xu, Yang Cao, Jue Wang, Yunfan Yang, Mei Huang   +5 more
doaj   +1 more source

c-Myc oncoprotein function

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1991
Genetic alterations of the c-myc locus in various malignancies and the ability of c-myc to transform cultured cells and induce tumors in transgenic animals attest to its central role in many neoplasms. By dissecting the c-Myc protein, a number of critical functional domains of c-Myc have been identified and characterized; these findings suggest a model
openaire   +2 more sources

Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription [PDF]

Oncogene, 2012
The transcription factor c-Myc has a critical role in cell proliferation and growth. The control of ribosome biogenesis by c-Myc through the regulation of transcription mediated by all three RNA polymerases is essential for c-Myc-driven proliferation. Specifically, in the nucleolus, c-Myc has been shown to be recruited to ribosomal DNA and activate RNA
Z, Li, S R, Hann
openaire   +2 more sources

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity [PDF]

Proceedings of the National Academy of Sciences, 2012
The oncogenic transcription factor c-Myc causes transformation and tumorigenesis, but it can also induce apoptotic cell death. Although tumor suppressors are necessary for c-Myc to induce apoptosis, the pathways and mechanisms are unclear.
Qin, Zhang, Erick, Spears, David N, Boone, Zhaoliang, Li, Mark A, Gregory, Stephen R, Hann   +5 more
openaire   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source